NELL1 and cancer: Subsequently, Caza et al. (9) reported that among patients with NELL-1 positive MN in the cohort, the proportion of those combined with malignant tumors was as high as 30%, suggesting that NELL-1 is a target antigen for MN associated with malignant tumors.